Aspectos farmacológicos da ivermectina e seu potencial uso no tratamento da COVID-19
| Autor: | Luana Amaral Pedroso, Nancy Scardua Binda, Andrea Grabe Guimarães, Mônica Cristina Teixeira |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
business.industry media_common.quotation_subject Pediculosis Pharmacology medicine.disease Clinical pharmacy Ivermectin Strongyloidiasis parasitic diseases medicine Scabies General Earth and Planetary Sciences Onchocerciasis business Lymphatic filariasis General Environmental Science media_common medicine.drug |
| Zdroj: | Brazilian Journal of Health and Pharmacy. 2:11-20 |
| ISSN: | 2596-321X |
| DOI: | 10.29327/226760.2.3-2 |
| Popis: | Ivermectin is a broad spectrum antiparasitic drug widely used in human and veterinary medicine. It is the drug of choice for the treatment of onchocerciasis, in addition to being approved for the treatment of lymphatic filariasis, strongyloidiasis, ascariasis, scabies and pediculosis. Ivermectin has antiparasitic activity in nanomolar concentrations, affecting the motility, feeding and reproduction of nematodes. Studies evaluated the antitumoral, antibacterial and antiviral effects of ivermectin, and also to treat metabolic diseases. Currently, the global interest on ivermectin is its potential benefit to treat COVID-19. In this study, the general aspects of pharmacology, physical and chemical characteristics, treatment protocols, safety aspects and toxicology of ivermectin were described, as well as properties that could or could not corroborate with its use in the treatment of COVID-19. A narrative review based on publications from the Pubmed database was performed using descriptors such as ivermectin, pharmacology, therapeutic use, safety, toxicity and COVID-19. It was observed that in addition to the broad therapeutic indication, ivermectin has extensive off-label use. Its antiviral activity seems to be due, both to its ability to stimulate the immune response, and to inhibit viral replication. However, its therapeutic safety to prevent or for COVID-19 treatment was not yet stablished, since the effective concentrations showed to be effective against the virus in in vitro studies indicate higher concentrations to be used than that approved for humans, what could enhance the side effects. In Brazil, the National Health Surveillance Agency (Anvisa) and the Brazilian Society of Clinical Pharmacy (SBFC) recently warned health professionals about ivermectin use off-label, and treatment protocols are not yet established for COVID-19. These official organizations support the use of ivermectin only for therapeutic indications registered at ANVISA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|